Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
KYMR
#901
Kymera Therapeutics, Inc. Common Stock
91.350
0
+1.44%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+1.44%
Monatliche Änderung
+25.93%
6 month change
+54.57%
Jahresänderung
+54.57%
Vorheriger Schlusskurs
90.050
0
Open
91.380
0
Bid
Ask
Low
91.350
0
High
91.380
0
Volumen
150
Märkte
Aktien
Gesundheitswesen
KYMR
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
44.81 M
51.7 M
55.18 M
61.11 M
64.94 M
81.64 M
—
Valuation ratios
Enterprise value
2.75 B
3.23 B
1.3 B
1.44 B
2.49 B
6 B
14.43 B
Price to earnings ratio
—
—
-8.66
-10.06
-13.5
-21.09
-58.15
Price to sales ratio
—
—
28.61
18.83
64.14
—
—
Price to cash flow ratio
—
—
-8.75
-14.39
-15.52
28.23
-13.71
Price to book ratio
—
—
2.73
3.75
3.61
4.16
7.04
Enterprise value to EBITDA ratio
—
—
—
—
-8.27
—
—
Profitability ratios
Return on assets %
0.09
0.17
0.26
0.26
0.23
0.18
0.26
Return on equity %
0.16
0.22
0.32
0.37
0.27
0.2
0.3
Return on invested capital %
65.97
160.54
290.93
—
—
199.2
—
Gross margin %
100
100
100
100
0
0
0
Operating margin %
136.05
138.03
344.37
210.62
555.82
891.07
7 830.73
EBITDA margin %
—
—
—
—
-640.16
-969.87
-8 054.78
Net margin %
133.96
137.6
330.6
186.99
475.57
794.04
6 967.04
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
2.73
4.88
5.88
4.73
7.53
10.47
34.66
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.07
0.13
0.08
0.13
0.06
0.03
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.84
1.76
2.59
2.76
2.83
EBIT per share
—
—
—
—
-4.11
-4.6
-4.68
EBITDA per share
—
—
—
—
-4.02
-4.5
-4.58
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
7.55
6.42
6.51
10.04
29.88
Net current asset value per share
—
—
7.78
6.94
6.8
10.31
31.67
Tangible book value per share
—
—
9.09
6.77
11.14
18.7
51.42
Working capital per share
—
—
6.45
5.48
5.9
9.33
28.04
Book value per share
—
—
9.09
6.77
11.14
18.7
51.42
Nachrichten
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress
Kymera Therapeutics: RBC Capital hebt Kursziel nach Pipeline-Fortschritten an
RBC Capital hebt Kursziel für Kymera Therapeutics wegen Pipeline-Potenzial an
RBC Capital raises Kymera Therapeutics price target on pipeline progress
RBC Capital raises Kymera Therapeutics price target on pipeline
Stifel bestätigt Kaufempfehlung für Kymera Therapeutics mit Kursziel von 114 US-Dollar
Stifel reiterates Buy rating on Kymera Therapeutics stock at $114
Kymera Q4 2025 slides: pipeline advances despite revenue miss
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics legt "At-the-Market"-Aktienprogramm im Volumen von 500 Millionen US-Dollar auf
Kymera Therapeutics launches $500 million at-the-market stock offering